Squarepoint
VIRX

Squarepoint’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Squarepoint’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-36,098
Closed -$20.6K – 4732
2023
Q4 		$20.6K Buy
+36,098
New +$22.2K ﹤0.01% 3910

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint's VIRX Position: Q1 2024 in Review

Squarepoint sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2024, closing a stake of 36,098 shares — an estimated $20.6K sold.

Squarepoint first reported a position in VIRX in Q4 2023 and held it in 1 quarter. The position peaked at $20.6K in Q4 2023. 40 funds tracked by Wall St. Rank hold VIRX as of Q1 2024.

  • Squarepoint reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Squarepoint sold 36,098 Viracta Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $20.6K.
  • Squarepoint first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Squarepoint's Viracta Therapeutics, Inc. Common Stock position peaked at $20.6K in Q4 2023.
  • 40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Squarepoint's 13F filing for Q1 2024, filed 15 May 2024.